Concepedia

Prevention of Cisplatin‐Induced Hearing Loss by Intratympanic Dexamethasone: A Randomized Controlled Study

Tal Marshak, Mariana Steiner, Margalith Kaminer, Levana Levy, Avi Shupak

Otolaryngology · 2014 · 127 citations · 33 references

DOI

Abstract

ITD significantly attenuated hearing loss at 6000 Hz and decreased the outer hair dysfunction in the DPOAE f2 range of 4000 to 8000 Hz. ITD might have potential in the reduction of Cisplatin-induced hearing loss.

References

33

Clinical Practice Guideline

Robert J. Stachler, Sujana S. Chandrasekhar, Sanford M. Archer et al. · Otolaryngology · 2012 · 904 citations

Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals

Su-Hua Sha, Ruth Taylor, Andrew Forge et al. · Hearing Research · 2001 · 403 citations

, , +10

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer

Carsten Bokemeyer, C. Berger, J T Hartmann et al. · British Journal of Cancer · 1998 · 333 citations · Full text

, , +8

Dexamethasone pharmacokinetics in the inner ear: Comparison of route of administration and use of facilitating agents

Sujana S. Chandrasekhar, Ran Y. Rubinstein, Jed A. Kwartler et al. · Otolaryngology · 2000 · 260 citations

Early Changes in Auditory Function As a Result of Platinum Chemotherapy: Use of Extended High-Frequency Audiometry and Evoked Distortion Product Otoacoustic Emissions

Kristin R. Knight, Dale F. Kraemer, Christiane Winter et al. · Journal of Clinical Oncology · 2007 · 230 citations · Full text